S&P 500 7,513.48 +0.94% NASDAQ 25,872.07 +1.43% DOW 52,334.21 +0.95% R2K 2,981.58 +1.33% VIX 17.07 -8.47% US 10Y 4.63 +0.61% DXY 101.11 +0.12% GOLD 4,075.50 +1.63% CRUDE 84.38 +1.38% BITCOIN 66,477.86 +1.91%
Next Bullish Trade
Sign in
RPRX

Royalty Pharma plc NMS · RPRX

$57.69 +0.40 (+0.70%)
Neutral · +0.78σ
+ Compare Open in Sniper

Price chart

Timeframe
Range
Fundamentals · free Click ▲ earnings markers (daily) for the day's move

Loading…

Latest bar · RPRX

Momentum reads · latest daily bar
Last
$57.25
-0.04 (-0.08%)
Mkt cap
$33.0B
Healthcare
RSI(14)
55.0
neutral
Stochastic %K
58.5
neutral
MFI(14)
58.7
neutral
ADX(14)
23.2
building

Green means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.

Financial overlay · last 12 quarters

The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.

QuarterRevenue Net incomeOp income FCFNet margin Op margin
2026-03-31 $0.6B $0.3B $0.6B $0.7B 46.7% 100.3%
2025-12-31 $0.6B $0.2B $0.4B $0.8B 34.4% 62.4%
2025-09-30 $0.6B $0.3B $0.4B $0.7B 47.3% 70.1%
2025-06-30 $0.6B $0.0B $0.2B $0.4B 5.2% 36.3%
2025-03-31 $0.6B $0.2B $0.5B $0.6B 42.1% 94.0%

Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.

Compare RPRX vs peers

Line RPRX up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.

Comparing RPRX no peers yet — add up to 4 below
Sector peers + LLY + UNH + JNJ + MRK + ABBV + PFE
Popular + AAPL + MSFT + NVDA + AMZN + GOOG + META + TSLA + AVGO
Matchups NVDA · AMD · AVGO · SMCI · MU AAPL · MSFT · GOOG · META · AMZN JPM · GS · MS · BAC · C TSLA · RIVN · LCID · GM · F XOM · CVX · OXY · COP

Add tickers to compare with RPRX

~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.

Earnings replay · last 20 reports

How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.

DateEPS actual EPS estSurprise Next-day
2026-05-06 1.30 1.18 +9.4% -1.0%
2026-02-11 1.47 1.33 +9.9% +1.2%
2025-11-05 1.17 1.04 +12.5% +0.9%
2025-08-06 1.14 1.03 +10.5% -0.3%
2025-05-08 1.06 0.95 +10.8% +0.1%
2025-02-11 1.15 1.05 +9.2% +0.3%
2024-11-06 1.04 0.93 +12.1% -0.5%
2024-08-08 0.96 0.97 -0.4% +0.4%
2024-05-09 0.98 0.98 -0.3% +0.4%
2024-02-15 1.52 1.00 +51.7% -0.4%
2023-11-08 0.79 0.77 +2.6% -0.8%
2023-08-08 0.84 0.81 +4.7% +0.0%
2023-05-09 1.60 1.27 +25.9% -0.4%
2023-02-15 1.56 1.46 +6.5% -1.2%
2022-11-08 0.73 0.71 +1.9% +0.8%
2022-08-04 0.79 0.78 +1.4% -0.1%
2022-05-05 0.60 0.72 -15.9% -2.6%
2022-02-15 0.80 0.78 +3.7% +0.4%
2021-11-10 0.73 0.70 +4.4% -3.3%
2021-08-11 0.71 0.71 +0.2% +1.9%

Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.

Peer comparison · Healthcare

Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.

Ticker ⇅ Mkt cap ⇅ P/E ⇅ Fwd P/E ⇅ P/S ⇅ EV/EBITDA ⇅ P/B ⇅ Gross M ⇅ Rev gr ⇅ EPS gr ⇅ FCF yld ⇅
RPRX ★ $33B 30.1 10.2 13.5 — 3.7 115.0% 11.0% 23.2% -2.97%
LLY — 43.9 — — — — — 55.5% — 0.84%
UNH — 32.1 — — — — — 2.0% — 4.57%
JNJ — 30.0 — — — — — 9.9% — 2.01%
MRK — 35.9 — — — — — 4.9% — 4.46%
ABBV — 121.1 — — — — — 12.4% — 4.79%
PFE — 18.4 — — — — — 5.4% — 9.03%
TMO — 29.3 — — — — — 6.2% — 2.78%

Auto-seeded from sector. Click any ticker to switch.

Ownership

Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.

Top institutional holders

Top-10 concentration: 43.06%

HolderShares% out
Morgan Stanley 43,571,633 9.83%
Capital International Investors 35,005,736 7.90%
Blackrock Inc. 25,907,745 5.84%
FMR, LLC 25,152,242 5.67%
BAILLIE GIFFORD & CO 16,155,677 3.64%
State Street Corporation 10,989,851 2.48%
Swedbank AB 10,726,608 2.42%
Capital World Investors 8,036,714 1.81%
Geode Capital Management, LLC 7,869,632 1.78%
Adage Capital Partners GP L.L.C. 7,480,633 1.69%

Insider activity · 90d

7 buys / 8 sells · ratio 0.88 · Finnhub

  • Urist Marshall SELL 0 @ $55.88
  • Hite Christopher SELL 40,000 @ $57.09
  • Hite Christopher SELL 40,600 @ $56.44
  • Hite Christopher SELL 459,399 @ $57.10
  • Hite Christopher SELL 461,953 @ $56.50
  • Urist Marshall SELL 9,099 @ $55.18
  • Hite Christopher SELL 559,399 @ $54.47
  • Hite Christopher SELL 676,991 @ $54.11
  • Engelbert Catherine M. BUY 55,673
  • Ho Carole BUY 4,545

Analyst estimates

Finnhub

What Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.

Low
$46.0
Mean
$59.88889
High
$66.0
Analysts
9
Recommendation distribution · period 2026-07-01
5
9
2
Revision trend (2026-04-01 → 2026-07-01): net 14 → 14 0 (net = strong_buy+buy − sell−strong_sell)

SEC filings

The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.

FormFiled DescriptionAction
4 2026-07-02 FORM 4 view ·
4 2026-07-02 FORM 4 view ·
4 2026-06-30 FORM 4 view ·
4 2026-06-25 FORM 4 view ·
4 2026-06-25 FORM 4 view ·
4 2026-06-08 FORM 4 view ·
4 2026-06-08 FORM 4 view ·
4 2026-06-08 FORM 4 view ·
4 2026-06-08 FORM 4 view ·
4 2026-06-08 FORM 4 view ·
4 2026-06-08 FORM 4 view ·
4 2026-06-08 FORM 4 view ·
4 2026-06-08 FORM 4 view ·
8-K 2026-06-04 8-K view ·
4 2026-05-28 FORM 4 view ·
8-K 2026-05-28 8-K view ·
4 2026-05-21 FORM 4 view ·
4 2026-05-15 FORM 4 view ·
4 2026-05-15 FORM 4 view ·
4 2026-05-08 FORM 4 view ·
4 2026-05-08 FORM 4 view ·
4 2026-05-08 FORM 4 view ·
4 2026-05-08 FORM 4 view ·
10-Q 2026-05-06 10-Q view ·
8-K 2026-05-06 8-K view ·
4 2026-04-30 FORM 4 view ·
8-K 2026-04-13 8-K view ·
DEF 14A 2026-04-10 DEF 14A view ·
4 2026-04-02 FORM 4 view ·
4 2026-03-31 FORM 4 view ·
4 2026-03-25 FORM 4 view ·
4 2026-03-04 FORM 4 view ·
4 2026-02-25 FORM 4 view ·
4 2026-02-13 FORM 4 view ·
4 2026-02-13 FORM 4 view ·
4 2026-02-13 FORM 4 view ·
4 2026-02-13 FORM 4 view ·
10-K 2026-02-11 10-K view ·
8-K 2026-02-11 8-K view ·
4 2026-02-04 FORM 4 view ·
4 2026-02-02 FORM 4 view ·
4 2026-01-26 FORM 4 view ·
4 2026-01-23 FORM 4 view ·
4 2026-01-20 FORM 4 view ·
4 2026-01-13 FORM 4 view ·
4 2026-01-06 FORM 4 view ·
4 2026-01-06 FORM 4 view ·
4 2026-01-02 FORM 4 view ·
4 2025-12-29 FORM 4 view ·
8-K 2025-12-22 8-K view ·
4 2025-12-22 FORM 4 view ·
8-K 2025-12-22 8-K view ·
4 2025-12-19 FORM 4 view ·
4 2025-12-17 FORM 4 view ·
4 2025-12-17 FORM 4 view ·
4 2025-12-09 FORM 4 view ·
4 2025-12-05 FORM 4 view ·
4 2025-12-03 FORM 4 view ·
4 2025-12-03 FORM 4 view ·
4 2025-11-26 FORM 4 view ·

About RPRX

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.

Options picks · RPRX

ITM + OTM ideas from the latest scan

Loading…

Congress trades · RPRX

STOCK Act disclosures

Loading…

SEC filings & insiders · RPRX

EDGAR · live

Loading…

Holders · RPRX

Institutions & insider activity

Loading…